Sp384

PANEL DISCUSSION

Date
May 7, 2023
Explore related products in the following collection:

Society: AGA

There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring. This session will review the role of historic and emerging biologics for management of CD and UC, examine comparative efficacy and safety and define the concepts of therapeutic drug monitoring, combinational biologic therapy, and rational de-escalation.

Presenters

Speaker Image for Gary Lichtenstein
University of Pennsylvania
Speaker Image for David Rubin
University of Chicago Division of the Biological Sciences

Tracks

Related Products

Thumbnail for ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Thumbnail for SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).
SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Thumbnail for THE IMPACT OF COVID-19 ON EARLY LIFE GUT MICROBIOME: IMPLICATIONS FROM TWO INDEPENDENT MOTHER-BABY DYAD COHORTS IN THE GREATER BAY AREA OF CHINA
THE IMPACT OF COVID-19 ON EARLY LIFE GUT MICROBIOME: IMPLICATIONS FROM TWO INDEPENDENT MOTHER-BABY DYAD COHORTS IN THE GREATER BAY AREA OF CHINA
BACKGROUND: Through shotgun metagenomic sequencing, we identified the depletion of probiotic species_ Lactobacillus acidophilus_ in stools of mice with non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC)…
Thumbnail for THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…